Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

KETOCONAZOLE

All products: general benefit

Other products in the same Health Canada class (J02A) — coverage varies; not interchangeable

  • Amphotericin b (Fungizone): general benefit
  • Fluconazole (Diflucan P.O.S.): general benefit, Limited Use 528, Not a benefit
  • Itraconazole (Sporanox): general benefit, Limited Use 570, Not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Caspofungin (Cancidas): not a benefit
  • Micafungin (Mycamine): not a benefit

1 more in the class list below

Apo-Ketoconazole · DIN 02237235 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ketoconazole · DIN 02237235 Manufacturer: Apotex Inc.; listing date 1999-09-15 Daily cost (source): $0.9393 Health Canada: Marketed since 2021-11-08 · brand APO-KETOCONAZOLE · ATC J02AB02 KETOCONAZOLE · form Tablet · route Oral · ingredients KETOCONAZOLE 200 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ketoconazole: Formulary list price $0.9393/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60554 · Verify on the e-Formulary ↗ (DIN 02237235)

Source record
DIN 02237235: Apo-Ketoconazole Raw flags: sec3=Y Item: 081204010; group id 12; item number 0015; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.9393; ministry $0.9393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60554 Therapeutic Notes (formulary) A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.
Interchangeable products
Nizoral · DIN 00633836 · not recorded Teva-Ketoconazole · DIN 02231061 · $0.9393
Shortage status: resolved shortage (ended 2020-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237235
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit (14) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS For the treatment of serious or life-threatening systemic fungal infections in normal, predisposed or immunocompromised patients where alternate therapy is considered inappropriate or has been unsuccessful: systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis and paracoccidioidomycosis, histoplasmosis and chromomycosis. Its use may also be considered in the treatment of severe, recalcitrant dermatophytoses unresponsive to other forms of therapy. The type of organism responsible for the infection should be identified; however, therapy may be initiated prior to obtaining these results, when clinically warranted. 1 Note: The treatment of fungal infections of the CNS is not recommended; ketoconazole penetrates poorly into the CNS. https://pdf.hres.ca/dpd_pm/00024529.PDF PM date: not printed or not captured Source product: TEVA-KETOCONAZOLE; DIN 02231061; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.